Payment overview · 2025
General Payments
$152.36
2 reported records · 2 companies
Healthcare provider profile · identity verified
John M Ferretti, DO
Allopathic & Osteopathic Physicians|Internal Medicine · ERIE, PA · NPI 1477518777
Verified facts
What the public records show
CMS Open Payments records show John M Ferretti, DO received $152.36 in general payments during 2025 across 2 reported records.
Novartis Pharmaceuticals Corporation accounted for 87.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $132.85 | 87.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.51 | 12.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $152.36 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $132.85 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 531 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 430 | 90 |
| Pantoprazole Sodium | Pantoprazole Sodium | 376 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 351 | 52 |
| Donepezil Hcl | Donepezil Hcl | 346 | 40 |
| Furosemide | Furosemide | 328 | 62 |
| Gabapentin | Gabapentin | 297 | 49 |
| Potassium Chloride | Potassium Chloride | 290 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 223 | 23 |
| Sertraline Hcl | Sertraline Hcl | 218 | 28 |
| Lisinopril | Lisinopril | 208 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 207 | 29 |
| Eliquis | Apixaban | 200 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 197 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 196 | 50 |
| Omeprazole | Omeprazole | 178 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 176 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 168 | 36 |
| Bumetanide | Bumetanide | 165 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 163 | 30 |
| Trazodone Hcl | Trazodone Hcl | 159 | 30 |
| Metformin Hcl | Metformin Hcl | 151 | 30 |
| Nifedipine Er | Nifedipine | 145 | 21 |
| Losartan Potassium | Losartan Potassium | 134 | 25 |
| Buspirone Hcl | Buspirone Hcl | 125 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 26 |
| Tramadol Hcl | Tramadol Hcl | 118 | 31 |
| Lorazepam | Lorazepam | 116 | 29 |
| Xarelto | Rivaroxaban | 115 | 27 |
| Myrbetriq | Mirabegron | 113 | 16 |
| Carvedilol | Carvedilol | 109 | 22 |
| Simvastatin | Simvastatin | 106 | 15 |
| Famotidine | Famotidine | 98 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 98 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 92 | 13 |
| Spironolactone | Spironolactone | 89 | 12 |
| Memantine Hcl | Memantine Hcl | 84 | suppressed |
| Mirtazapine | Mirtazapine | 84 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 77 | 45 |
| Rexulti | Brexpiprazole | 76 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 15 |
| Meloxicam | Meloxicam | 72 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 64 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | 11 |
| Baclofen | Baclofen | 62 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 62 | 12 |
| Jardiance | Empagliflozin | 61 | 16 |
| Latanoprost | Latanoprost | 61 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | 11 |
| Olanzapine | Olanzapine | 58 | 12 |
| Levetiracetam | Levetiracetam | 57 | suppressed |
| Finasteride | Finasteride | 56 | 12 |
| Pregabalin | Pregabalin | 55 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | suppressed |
| Allopurinol | Allopurinol | 51 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 51 | suppressed |
| Lactulose | Lactulose | 50 | 18 |
| Metformin Hcl Er | Metformin Hcl | 50 | suppressed |
| Ibuprofen | Ibuprofen | 49 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 48 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 48 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 19 |
| Methocarbamol | Methocarbamol | 46 | 15 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 45 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 45 | suppressed |
| Celecoxib | Celecoxib | 45 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 43 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 41 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | suppressed |
| Clozapine | Clozapine | 39 | suppressed |
| Ketoconazole | Ketoconazole | 39 | suppressed |
| Alprazolam | Alprazolam | 38 | suppressed |
| Atenolol | Atenolol | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 26 |
| Morphine Sulfate | Morphine Sulfate | 37 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 36 | 14 |
| Glipizide | Glipizide | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 35 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 14 |
| Tradjenta | Linagliptin | 34 | suppressed |
| Cephalexin | Cephalexin | 33 | 20 |
| Lansoprazole | Lansoprazole | 32 | suppressed |
| Nyamyc | Nystatin | 32 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 25 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Fluconazole | Fluconazole | 24 | 13 |
| Timolol Maleate | Timolol Maleate | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 18 |
| Nystatin | Nystatin | 23 | 11 |
| Ozempic | Semaglutide | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | 12 |
| Methenamine Hippurate | Methenamine Hippurate | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | 12 |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 17 |
| Sevelamer Carbonate | Sevelamer Carbonate | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | 12 |
| Metolazone | Metolazone | 18 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Zonisade | Zonisamide | 16 | suppressed |
| Admelog | Insulin Lispro | 15 | suppressed |
| Briviact | Brivaracetam | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 12 |
| Gemtesa | Vibegron | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Lorazepam Intensol | Lorazepam | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Dapsone | Dapsone | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Renacidin | Citric Ac/Gluconolact/Mag Carb | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 12 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Belbuca | Buprenorphine Hcl | 11 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Loxapine | Loxapine Succinate | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Sulindac | Sulindac | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $152.36 · 2 records | Novartis Pharmaceuticals Corporation | Cologuard Collection Kit, LEQVIO | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novartis Pharmaceuticals Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error